Overview

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis while on a background treatment of methotrexate. This study is comprised of 3 periods: Period 1: 52-week blinded treatment Period 2: additional 48-week unblinded treatment Period 3: 48-week post-treatment follow-up
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Antibodies, Monoclonal
Methotrexate